|, NAT1, NET, NET1, SLC6A5, solute carrier family 6 member 2, Norepinephrine transporter|
|Targeted by Drug|
|amitriptyline, amoxapine, atomoxetine, bupropion, citalopram, clomipramine, desipramine, desvenlafaxine, Dextroamphetamine, duloxetine, Imipramine, levomilnacipran, lofepramine, maprotiline, mazindol, methylphenidate, nefazodone, nisoxetine, nomifensine, nortriptyline, phenelzine, protriptyline, quetiapine, reboxetine, sibutramine, tapentadol, trimipramine, venlafaxine, zotepine|
|RNA expression pattern|
|View/Edit Human||View/Edit Mouse|
NET is a monoamine transporter and is responsible for the sodium-chloride (Na+/Cl−)-dependent reuptake of extracellular norepinephrine (NE), which is also known as noradrenaline. NET can also reuptake extracellular dopamine (DA). The reuptake of these two neurotransmitters is essential in regulating concentrations in the synaptic cleft. NETs, along with the other monoamine transporters, are the targets of many antidepressants and recreational drugs. In addition, an overabundance of NET is associated with ADHD. There is evidence that single-nucleotide polymorphisms in the NET gene (SLC6A2) may be an underlying factor in some of these disorders.
- 1 Gene
- 2 Structure
- 3 Function
- 4 Transport mechanisms
- 5 Location in the nervous system
- 6 Regulation
- 7 Clinical significance
- 8 Therapeutic uses
- 9 Psychostimulants
- 10 Further research
- 11 Imaging
- 12 See also
- 13 References
- 14 External links
The norepinephrine transporter gene, SLC6A2 is located on human chromosome 16 locus 16q12.2. This gene is encoded by 14 exons. Based on the nucleotide and amino acid sequence, the NET transporter consists of 617 amino acids with 12 membrane-spanning domains. The structural organization of NET is highly homologous to other members of a sodium/chloride-dependent family of neurotransmitter transporters, including dopamine, epinephrine, serotonin and GABA transporters.
Single nucleotide polymorphisms
A single-nucleotide polymorphism (SNP) is a genetic variation in which a genome sequence is altered by a single nucleotide (A, T, C or G). NET proteins with an altered amino acid sequence (more specifically, a missense mutation) could potentially be associated with various diseases that involve abnormally high or low plasma levels of norepinephrine due to altered NET function. NET SNPs and possible associations with various diseases are an area of focus for many research projects. There is evidence suggesting a relationship between NET SNPs and various disorders such as ADHD psychiatric disorders, postural tachycardia and orthostatic intolerance. The SNPs rs3785143 and rs11568324 have been related to attention-deficit hyperactivity disorder. Thus far, however, the only confirmed direct association between a SNP and a clinical condition is that of the SNP, Ala457Pro, and orthostatic intolerance. Thirteen NET missense mutations have been discovered so far.
|Location||Amino Acid Variant||TMD (if known)||Related Disease|
|Exon 2||Val69Ile||TMD 1||None|
|Exon 3||Thr99Ile||TMD 2||None|
|Exon 5||Val245Ile||TMD 4||None|
|Exon 10||Val449Ile||TMD 9||None|
|Exon 10||Ala457Pro||TMD 9||Orthostatic intolerance|
|Exon 11||Gly478Ser||TMD 10||None|
For the table above, refer to this table of standard amino acid abbreviations. This notation for
missense mutations, take Val69Ile for example, indicates that amino acid Val69 was changed to Ile.
An epigenetic mechanism (hypermethylation of CpG islands in the NET gene promoter region) that results in reduced expression of the noradrenaline (norepinephrine) transporter and consequently a phenotype of impaired neuronal reuptake of norepinephrine has been implicated in both postural orthostatic tachycardia syndrome and panic disorder.
The norepinephrine transporter is composed of 12 transmembrane domains (TMDs). The intracellular portion contains an amino (-NH
2) group and carboxyl (-COOH) group. In addition, there is a large extracellular loop located between TMD 3 and 4. The protein is composed of 617 amino acids.
NET functions to transport synaptically released norepinephrine back into the presynaptic neuron. As much as 90% of the norepinephrine released will be taken back up in the cell by NET. NET functions by coupling the influx of sodium and chloride (Na+/Cl−) with the transport of norepinephrine. This occurs at a fixed ratio of 1:1:1. Both the NET and the dopamine transporter (DAT) can transport norepinephrine and dopamine. The reuptake of norepinephrine and dopamine is essential in regulating the concentration of monoamine neurotransmitters in the synaptic cleft. The transporter also helps maintain homeostatic balances of the presynaptic neuron.
Norepinephrine (NE) is released from noradrenergic neurons that innervate both the CNS and PNS. NE, also known as noradrenaline (NA), has an important role in controlling mood, arousal, memory, learning, and pain perception. NE is a part of the sympathetic nervous system. Dysregulation of the removal of norepinephrine by NET is associated with many neuropsychiatric diseases, discussed below . In addition, many antidepressants and recreational drugs compete for the binding of NET with NE.
The transport of norepinephrine back into presynaptic cell is made possible by the cotransport with Na+ and Cl−. The sequential binding of the ions results in the eventual reuptake of norepinephrine. The ion gradients of Na+ and Cl− make this reuptake energetically favorable. The gradient is generated by the Na+/K+-ATPase which transports three sodium ions out and two potassium ions into the cell. NETs have conductances similar to those of ligand-gated ion channels. The expression of NET results in a leak-channel activity.
Location in the nervous system
NETs are restricted to noradrenergic neurons and are not present on neurons that release dopamine or epinephrine. The transporters can be found along the cell body, axons, and dendrites of the neuron. NETs are located away from the synapse, where norepinephrine is released. They are found closer to the plasma membrane of the cell. This requires norepinephrine to diffuse from the site it is released to the transporter for reuptake. Norepinephrine transporters are confined to the neurons of the sympathetic system, and those innervating the adrenal medulla, lung, and placenta.
Regulation of NET function is complex and a focus of current research. NETs are regulated at both the cellular and molecular level post-translation. The most understood mechanisms include phosphorylation by the second messenger protein kinase C (PKC). PKC has been shown to inhibit NET function by sequestration of the transporter from the plasma membrane. The amino acid sequence of NET has shown multiple sites related to protein kinase phosphorylation. Post-translational modifications can have a wide range of effects on the function of the NET, including the rate of fusion of NET-containing vesicles with the plasma membrane, and transporter turnover.
Orthostatic intolerance (OI) is a disorder of the autonomic nervous system (a subcategory of dysautonomia) characterized by the onset of symptoms upon standing. Symptoms include fatigue, lightheadedness, headache, weakness, increased heart rate/heart palpitations, anxiety, and altered vision. Often, patients have high plasma norepinephrine (NE) concentrations (at least 600 pg/ml) in relation to sympathetic outflow upon standing, suggesting OI is a hyperadrenergic condition. The discovery of identical twin sisters both suffering from OI suggested a genetic basis for the disorder. A missense mutation on the NET gene (SLC62A) was discovered in which an alanine residue was replaced with a proline residue (Ala457Pro) in a highly conserved region of the transporter. The patients’ defective NET had only 2% of the activity of the wild-type version of the gene. The genetic defect in the NET protein results in decreased NET activity that could account for abnormally high NE plasma levels in OI. However, 40 other OI patients did not have the same missense mutation, indicating other factors contributed to the phenotype in the identical twins. This discovery of the linkage with NET mutations that results in decreased norepinephrine reuptake activity and orthostatic intolerance suggests faulty NE uptake mechanisms can contribute to cardiovascular disease.
Inhibition of the norepinephrine transporter (NET) has potential therapeutic applicationsin the treatment of attention deficit hyperactivity disorder (ADHD), substance abuse, neurodegenerative disorders (e.g., Alzheimer's disease (AD) and Parkinson's disease (PD)) and clinical depression.
Major depressive disorder
Certain antidepressant medications act to raise noradrenaline, such as serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), norepinephrine reuptake inhibitors (NRIs or NERIs) and the tricyclic antidepressants (TCAs). The mechanism by which these medications work is that the reuptake inhibitors prevent the reuptake of serotonin and norepinephrine by the presynaptic neuron, paralyzing the normal function of the NET. At the same time, higher levels of 5-HT are maintained in the synapse increasing the concentrations of the latter neurotransmitters. Since the noradrenaline transporter is responsible for most of the dopamine clearance in the prefrontal cortex, SNRIs block reuptake of dopamine too, accumulating the dopamine in the synapse. However, DAT, the primary way dopamine is transported out of the cell, can work to decrease dopamine concentration in the synapse when the NET is blocked. For many years, the number one choice in treating mood disorders like depression was through administration of TCAs, such as desipramine (Norpramin), nortriptyline (Arentyl, Pamelor), protriptyline (Vivactil) and amoxapine (Asendin). SSRIs, which mainly regulate serotonin, subsequently replaced tricyclics as the primary treatment option for depression because of their better tolerability and lower incidence of adverse effects.
Many drugs exist in the treatment of ADHD. Dextroamphetamine (Dexedrine, Dextrostat), Adderall, methylphenidate (Ritalin, Metadate, Concerta, Daytrana), and lisdexamfetamine (Vyvanse) block reabsorption of the catecholamines dopamine and norepinephrine through monoamine transporters (including NET), thereby increasing levels of these neurotransmitters in the brain. The strong selective norepinephrine reuptake inhibitor (NRI), atomoxetine (Strattera), has been approved by the U.S. Food and Drug Administration (FDA) to treat ADHD in adults. The role of the NET in ADHD is similar to how it works to ease the symptoms of depression. The NET is blockaded by atomoxetine and increases NE levels in the brain. It can work to increase one's ability to focus, decrease any impulsiveness, and lessen hyperactivity in both children and adults who suffer from ADHD.
Cocaine is a powerful psychostimulant and known to be one of the most widely abused substances. Cocaine is a nonselective, reuptake inhibitor of the norepinephrine, serotonin, and dopamine transporters. This thwarts the absorption of these chemicals into the presynaptic terminal and allows a large concentration of dopamine, serotonin and norepinephrine to build up in the synaptic cleft. The potential for cocaine addiction is thought to be a result of its effects on dopamine transporters in the CNS, while it has been suggested that the life-threatening cardiovascular effects of cocaine may involve the inhibition of NETs at sympathetic and CNS autonomic synapses.
Amphetamines have a similar effect on norepinephrine levels compared to that of cocaine in that they both increase NE levels in the brain. Amphetamine-like drugs are substrates for monoamine transporters, include NET, that cause a reversal in the direction of neurotransmitter transport. Amphetamines cause a large accumulation of extracellular NE. High levels of NE in the brain account for most of the profound effects of amphetamines, including alertness, anorectic, locomotor and sympathomimetic effects. However, the effects that amphetamines have on the brain are slower but last longer than the effects cocaine has on the brain. MDMA (3,4-Methylenedioxymethamphetamine or "ecstasy") is an amphetamine with wide recreational use. A study reported that the NET inhibitor reboxetine reduced the stimulant effects of MDMA in humans, demonstrating the crucial role NET has in the cardiovascular and stimulant-like effects of MDMA.
The role of the NET in many brain disorders underlies the importance of understanding the (dys)regulation of the transporter. A complete model of the proteins that associate with the transporter will be useful in designing drug therapies for diseases such as schizophrenia, affective disorder, and autonomic disorders. Recently discovered mechanisms of the NET, including the ability to act reversibly and as an ion channel, provide other areas of research.
The role of NE in schizophrenia has not been fully understood, but has stimulated research into this topic. The only relationship that has been understood between researchers is that there is a positive correlation between increased NE levels in the brain and spinal fluid (CSF) and activity of schizophrenia. In one study, clonidine, a drug used to treat medical conditions such as ADHD and high blood pressure, was shown to produce a significant decrease in plasma level MHPG (3-methoxy-4-hydroxyphenylglycol), a metabolite of NE, in the normal control group, but not in the group of schizophrenic patients. This suggests that in schizophrenia, the alpha-2 adrenergic receptor, a presynaptic inhibitory receptor, may be less sensitive compared to normally functioning alpha-2 receptors and thus relate to elevated NE levels in the disorder. In addition to increased NE levels in the brain and CSF, increased levels of MHPG has also been associated with a diagnosis of schizophrenia. Impaired NE regulation in schizophrenia has been an area of interest for researchers and research on this topic is still ongoing.
- Neurotransmitter transporter
- Sodium:neurotransmitter symporter
- Solute carrier family
- Monoamine transporter
- Orthostatic intolerance
- Single-nucleotide polymorphisms
- "Drugs that physically interact with Sodium-dependent noradrenaline transporter view/edit references on wikidata".
- "Human PubMed Reference:".
- "Mouse PubMed Reference:".
- Pacholczyk T, Blakely RD, Amara SG (Mar 1991). "Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter". Nature. 350 (6316): 350–4. doi:10.1038/350350a0. PMID 2008212.
- Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD (May 2000). "Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter". The Journal of Comparative Neurology. 420 (2): 211–32. doi:10.1002/(SICI)1096-9861(20000501)420:2<211::AID-CNE5>3.0.CO;2-3. PMID 10753308.
- Tellioglu T, Robertson D (Nov 2001). "Genetic or acquired deficits in the norepinephrine transporter: current understanding of clinical implications". Expert Reviews in Molecular Medicine. 2001 (29): 1–10. doi:10.1017/S1462399401003878. PMID 14987367.
- Kim CH, Hahn MK, Joung Y, Anderson SL, Steele AH, Mazei-Robinson MS, Gizer I, Teicher MH, Cohen BM, Robertson D, Waldman ID, Blakely RD, Kim KS (Dec 2006). "A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder". Proceedings of the National Academy of Sciences of the United States of America. 103 (50): 19164–9. doi:10.1073/pnas.0510836103. PMC . PMID 17146058.
- Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D (Feb 2000). "Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency". The New England Journal of Medicine. 342 (8): 541–9. doi:10.1056/NEJM200002243420803. PMID 10684912.
- Kim JW, Biederman J, McGrath CL, Doyle AE, Mick E, Fagerness J, Purcell S, Smoller JW, Sklar P, Faraone SV (Jun 2008). "Further evidence of association between two NET single-nucleotide polymorphisms with ADHD". Molecular Psychiatry. 13 (6): 624–30. doi:10.1038/sj.mp.4002090. PMID 17876324.
- Maarten E. A. Reith (2002). Neurotransmitter transporters: structure, function, and regulation. Humana Press. p. 120. ISBN 978-0-89603-945-2. Retrieved 27 October 2011.
- Esler M, Alvarenga M, Pier C, Richards J, El-Osta A, Barton D, Haikerwal D, Kaye D, Schlaich M, Guo L, Jennings G, Socratous F, Lambert G (Jul 2006). "The neuronal noradrenaline transporter, anxiety and cardiovascular disease". Journal of Psychopharmacology. 20 (4 Suppl): 60–6. doi:10.1177/1359786806066055. PMID 16785272.
- Stöber G, Nöthen MM, Pörzgen P, Brüss M, Bönisch H, Knapp M, Beckmann H, Propping P (Nov 1996). "Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders". American Journal of Medical Genetics. 67 (6): 523–32. doi:10.1002/(SICI)1096-8628(19961122)67:6<523::AID-AJMG3>3.0.CO;2-I. PMID 8950409.
- Sager JJ, Torres GE (Aug 2011). "Proteins interacting with monoamine transporters: current state and future challenges". Biochemistry. 50 (34): 7295–310. doi:10.1021/bi200405c. PMID 21797260.
- Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD (Oct 1995). "Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants". The Journal of Experimental Biology. 198 (Pt 10): 2197–212. PMID 7500004.
- Torres GE, Gainetdinov RR, Caron MG (Jan 2003). "Plasma membrane monoamine transporters: structure, regulation and function". Nature Reviews. Neuroscience. 4 (1): 13–25. doi:10.1038/nrn1008. PMID 12511858.
- Zhou J (Dec 2004). "Norepinephrine transporter inhibitors and their therapeutic potential". Drugs of the Future. 29 (12): 1235–1244. doi:10.1358/dof.2004.029.12.855246. PMC . PMID 16871320.
- Gether U, Andersen PH, Larsson OM, Schousboe A (Jul 2006). "Neurotransmitter transporters: molecular function of important drug targets". Trends in Pharmacological Sciences. 27 (7): 375–83. doi:10.1016/j.tips.2006.05.003. PMID 16762425.
- Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I, Luft FC, Jordan J (Jan 2002). "Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance". Circulation. 105 (3): 347–53. doi:10.1161/hc0302.102597. PMID 11804991.
- Morón JA, Brockington A, Wise RA, Rocha BA, Hope BT (Jan 2002). "Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines". The Journal of Neuroscience. 22 (2): 389–95. PMID 11784783.
- Yavich L, Forsberg MM, Karayiorgou M, Gogos JA, Männistö PT (Sep 2007). "Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum". The Journal of Neuroscience. 27 (38): 10196–209. doi:10.1523/JNEUROSCI.0665-07.2007. PMID 17881525.
- Clinical Pharmacology of SSRI's: How SSRIs as a Group Differ From TCAs, Preskorn
- "What medications are used to treat ADHD?". National Institutes of Mental Health.
- Simpson D, Plosker GL (2004). "Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder". Drugs. 64 (2): 205–22. doi:10.2165/00003495-200464020-00005. PMID 14717619.
- "Atomoxetine -". PubMed Health. Retrieved 2 November 2011.
- Macey DJ, Smith HR, Nader MA, Porrino LJ (Jan 2003). "Chronic cocaine self-administration upregulates the norepinephrine transporter and alters functional activity in the bed nucleus of the stria terminalis of the rhesus monkey". The Journal of Neuroscience. 23 (1): 12–6. PMID 12514195.
- Barker EL, Blakely RD (1995). "Norepinephrine and Serotonin Transporters". In Kupfer DJ, Bloom FE. Psychopharmacology: the fourth generation of progress. New York: Raven Press. ISBN 0-7817-0166-X. Retrieved 2 November 2011.
- Drug and Human Performance Fact Sheets. "Methamphetamine (And Amphetamine)". Retrieved 1 November 2011
- Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A (May 1995). "Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport". The Journal of Neuroscience. 15 (5 Pt 2): 4102–8. PMID 7751968.
- Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (Aug 2011). "The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans". Clinical Pharmacology and Therapeutics. 90 (2): 246–55. doi:10.1038/clpt.2011.78. PMID 21677639.
- Decaire, Michael. "The neurophysiology of schizophrenia: Etiology and Psychopharmacological treatment". Retrieved 1 November 2011
- Breier A, Wolkowitz OM, Roy A, Potter WZ, Pickar D (Nov 1990). "Plasma norepinephrine in chronic schizophrenia". The American Journal of Psychiatry. 147 (11): 1467–70. doi:10.1176/ajp.147.11.1467. PMID 2221157.
- Sternberg DE, Charney DS, Heninger GR, Leckman JF, Hafstad KM, Landis DH (Mar 1982). "Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of clonidine in schizophrenic patients and normal controls". Archives of General Psychiatry. 39 (3): 285–9. doi:10.1001/archpsyc.1982.04290030025004. PMID 6279049.
- van Kammen DP, Antelman S (Apr 1984). "Impaired noradrenergic transmission in schizophrenia?". Life Sciences. 34 (15): 1403–13. doi:10.1016/0024-3205(84)90054-7. PMID 6323903.
- Rami-Mark C, Berroterán-Infante N, Philippe C, Foltin S, Vraka C, Hoepping A, Lanzenberger R, Hacker M, Mitterhauser M, Wadsak W (Dec 2015). "Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [(11)C]ME@HAPTHI". EJNMMI Research. 5 (1): 113. doi:10.1186/s13550-015-0113-3. PMC . PMID 26061602.